Strategic Licensing Puma Biotechnology has a history of strategic licensing and partnerships, including the exclusive license for alisertib with Takeda and ongoing collaborations. This presents opportunities to position complementary oncology assets, co-development discussions, or licensing partnerships that expand the portfolio and leverage existing R&D and regulatory pathways.

HER2+ Focus The company is actively engaged in HER2 positive breast cancer therapies, suggesting sales opportunities in oncology product lines or companion diagnostics that align with HER2 targeting strategies and potential clinical trial collaborations in breast cancer indications.

Investor & Conference Presence Regular participation in major investment conferences signals a cadence of potential capital raising, strategic partnerships, or milestone-driven collaborations. This can be leveraged to pitch co-development, research funding, or strategic alliances with larger biotech and pharma partners.

R&D Continuity With a focus on anti-cancer drug alisertib and a robust funding level, there is room to explore opportunities around clinical trial support services, CRO partnerships, and data-driven pharmacovigilance, as well as regional expansion for development activities.

Security & Compliance Past data breach investigations underscore the importance of robust data security and compliance. This creates a sales angle for cybersecurity solutions, regulated data handling, and vendor risk assessments when engaging with Puma for collaboration or services.